capecitabine has been researched along with Carcinoma, Hepatocellular in 57 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 20 (35.09) | 29.6817 |
| 2010's | 29 (50.88) | 24.3611 |
| 2020's | 8 (14.04) | 2.80 |
| Authors | Studies |
|---|---|
| Bao, D; Chen, Z; Hu, J; Ji, J; Li, D; Li, X; Liu, S; Pang, Y; Qian, Y; Shi, M; Wang, H; Xu, L; Xu, X; Yi, C; Zhang, X; Zhou, Y | 1 |
| Cao, L; Chen, T; Duan, J; Kong, D; Lu, J; Ren, J; Shen, Z; Sun, Q; Wang, H; Wang, Z; Yang, R; Yoshida, S; Zheng, H | 1 |
| Şener, N; Yakupoğlu, A | 1 |
| El-Badawy, O; Eldin, AS; Fakhry, H; Hassan, EA; Hetta, HF; Rayan, A; Soliman, A; Zahran, AM | 1 |
| Changou, CA; Chen, LT; Cheng, YC; Liu, S; Liu, SH; Luh, F; Shiah, HS; Yen, Y | 1 |
| Wilhelmi, M | 1 |
| de Liguori Carino, N; Hubner, RA; Kapacee, ZA; Lamarca, A; McNamara, MG; Valle, JW | 1 |
| Brandi, G; Brocchi, S; De Lorenzo, S; Di Federico, A; Frega, G; Golfieri, R; Morelli, MC; Palloni, A; Rizzo, A; Vasuri, F | 1 |
| Carilli, A; Pellini Ferreira, B; Vasquez, J | 1 |
| Bansal, P; Fekrazad, HM; Lee, FC; Patt, Y; Rojas-Hernandez, C | 1 |
| Barbera, MA; Brandi, G; Cescon, M; Cucchetti, A; De Lorenzo, S; De Pace, V; Del Gaudio, M; Frega, G; Maroni, L; Neri, F; Palloni, A; Pantaleo, MA; Pinna, AD; Ravaioli, M; Ripoli, MC | 1 |
| Andreesen, R; Endlicher, E; Ghibelli, L; Hackl, C; Herr, W; Klebl, F; Reichle, A; Schulz, U; Vogelhuber, M; Walter, I; Wiedmann, K; Wiest, R | 1 |
| Barbera, MA; Bernardi, M; Brandi, G; Casadei Gardini, A; De Lorenzo, S; Di Costanzo, GG; Foschi, FG; Garuti, F; Granito, A; Inghilesi, AL; Marra, F; Sacco, R; Tortora, R; Tovoli, F; Trevisani, F | 1 |
| Abbati, F; Barbera, MA; Brandi, G; De Lorenzo, S; Frega, G; Garajovà, I; Garuti, F; Golfieri, R; Palloni, A; Pantaleo, MA; Saccoccio, G; Venturi, M | 1 |
| Barbera, MA; Brandi, G; De Lorenzo, S; Frega, G; Garajovà, I; Garuti, F; Palloni, A; Rizzo, A; Tovoli, F; Trevisani, F | 1 |
| Dadduzio, V; Farinati, F; Giovanis, P; Imondi, A; Lombardi, G; Lonardi, S; Maddalo, G; Pastorelli, D; Pelizzaro, F; Peserico, G; Rizzato, MD; Sammarco, A; Sartori, A; Soldà, C | 1 |
| Abdel-Rahman, O; Abdel-Wahab, M; Abdel-Wahab, S; Elbassiony, M; Ellithy, M; Shaker, M | 1 |
| Dong, JC; He, SL; Liu, LM; Shen, J; Sun, XJ; Zhu, XJ | 1 |
| Byun, KS; Kang, K; Kang, SH; Kim, JH; Lee, HJ; Lee, SJ; Suh, SJ; Yeon, JE; Yim, HJ; Yoo, YJ; Yoon, EL | 1 |
| Agostini, V; Andreone, P; Biasco, G; Bolondi, L; Brandi, G; Cucchetti, A; de Rosa, F; di Girolamo, S; Golfieri, R; Gramenzi, A; Pinna, AD; Sama, C; Serra, C; Trevisani, F | 1 |
| Chiba, T; Kanai, F; Kanogawa, N; Motoyama, T; Ogasawara, S; Ooka, Y; Suzuki, E; Tawada, A; Yokosuka, AO | 1 |
| Cheng, AL; Ho, MC; Hsu, CH; Shao, YY | 1 |
| Benevento, F; Bolondi, L; Granito, A; Marinelli, S; Piscaglia, F; Renzulli, M; Terzi, E; Venerandi, L | 1 |
| Hao, XB; He, ZH; Hong, T; Huang, F; Huang, MZ; Jiang-Zheng, Z; Lei, JH; Lu, YD; Wang-Yuan, Z | 1 |
| Farinati, F; Murer, F; Peserico, G; Pozzan, C | 1 |
| Binkhorst, L; Bins, S; Mathijssen, R; van Doorn, L; Veelenturf, S | 1 |
| Brunetti, O; Casadei Gardini, A; Cascinu, S; Ercolani, G; Faloppi, L; Foca, F; Foschi, FG; Frassineti, GL; Marisi, G; Pisconti, S; Rudnas, B; Scartozzi, M; Silvestris, N; Tamburini, E; Tassinari, D; Valgiusti, M | 1 |
| Finn, RS; Zhu, AX | 1 |
| Bang, YJ; Im, SA; Kim, JH; Kim, TY; Lee, JO; Lee, KW; Oh, DY | 1 |
| Al-Osaimi, AM; Angle, JF; Argo, C; Berg, C; Caldwell, S; Hagspiel, KD; McIntosh, A; Northup, P; Rich, TA; Weiss, G | 1 |
| Cheng, YC; Chu, E; Foo, A; Jiang, Z; Liu, SH; Rose, M; Saif, MW; So, S; Su, T; Yen, Y | 1 |
| Chao, TY; Chen, PJ; Cheng, AL; Epstein, RJ; Hsiao, LT; Hsu, C; Hsu, CH; Lin, ZZ; Toh, HC; Yang, TS | 1 |
| Bang, YJ; Han, SW; Im, SA; Kim, JW; Kim, TY; Lee, JO; Oh, DY | 1 |
| Li, J; Qiu, Y; Shen, F; Shi, L; Wang, K; Wu, M; Xi, T; Xia, Y; Yan, Z | 1 |
| Caparro, M; Giantonio, B; Haller, DG; Mykulowycz, K; O'Dwyer, PJ; Olthoff, K; Reddy, R; Rosen, M; Shaked, A; Sohal, D; Soulen, MC; Sun, W; Teitelbaum, UR | 1 |
| Ang, SF; Choo, SP; Foo, KF; Ong, SY; Poon, DY; Tan, SH; Toh, HC | 1 |
| Acalovschi, M; Aldea, M; Fischer-Fodor, E; Irimie, A; Kacso, G; Mosteanu, O; Petrushev, B; Pop, T; Soritau, O; Susman, S; Tomuleasa, C | 1 |
| Cheng, AL; Hsu, CH; Huang, CC; Lin, SD; Shao, YY | 1 |
| Aldea, M; Berindan-Neagoe, I; Cristea, V; Dudea, M; Florea, A; Irimie, A; Kacso, G; Mosteanu, O; Orza, A; Pall, E; Petrushev, B; Soritau, O; Susman, S; Tomuleasa, C | 1 |
| Jiang, X; Wang, YX; Yan, D; Yan, S; Yang, J | 1 |
| Jang, JW; Kay, CS; Kim, JY; Kim, KJ; Kwon, JH; Yoo, EJ | 1 |
| Fan, J; Ji, Y; Li, XM; Liu, YK; Shi, YH; Sun, QM; Tang, ZY; Wu, ZQ; Xiao, YS; Ye, SL; Zhou, J | 1 |
| Fan, J; Liu, YK; Sun, QM; Tang, ZY; Wu, ZQ; Xiao, YS; Xue, Q; Ye, SL; Zhao, Y; Zhou, J | 1 |
| Aguayo, A; Brown, TD; Charnsangavej, C; Curley, SA; Ellis, LM; Hassan, MM; Lozano, RD; Nooka, AK; Patt, YZ; Schnirer, II; Vauthey, JN; Wolff, RA | 1 |
| Boyer, JC; Ciccolini, J; Dahan, L; Dales, JP; Durand, A; Evrard, A; Lacarelle, B; Mercier, C; Milano, G; Richard, K; Seitz, JF | 1 |
| Bai, LY; Chen, PM; Poh, SB | 1 |
| Bang, SM; Cho, EK; Han, SH; Kim, JH; Kim, SS; Kwon, OS; Kwon, SY; Lee, JH; Lee, JN; Lee, Y; Park, SH; Park, YH; Shin, DB | 1 |
| Lim, ST; Ong, S; Quek, R | 1 |
| Diasio, R; Saif, MW | 1 |
| Bearz, A; Berretta, M; Di Benedetto, F; Lleshi, A; Spina, M; Tirelli, U | 1 |
| Blanc, JF; Boige, V; Bouché, O; Dahan, L; Ducreux, M; Dupouy, N; Jouve, JL; Pignon, JP; Raoul, JL | 1 |
| Saif, MW; Tejani, MA | 1 |
| Eckel, F; Lersch, C; Mayr, M; Schmid, RM; Schulte-Frohlinde, E; Stock, K; von Delius, S | 1 |
| Han, CJ | 1 |
| Kim, CM; Lee, WJ; Nam, BH; Park, JW; Shim, JH | 1 |
| Fan, J; Tang, Z; Zhou, J | 1 |
| Aguayo, A; Patt, YZ | 1 |
4 review(s) available for capecitabine and Carcinoma, Hepatocellular
| Article | Year |
|---|---|
Targeting angiogenesis in hepatocellular carcinoma: focus on VEGF and bevacizumab.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Capecitabine; Carcinoma, Hepatocellular; Clinical Trials as Topic; Cytotoxins; Deoxycytidine; Erlotinib Hydrochloride; Fluorouracil; Gemcitabine; Humans; Liver Neoplasms; Neoplasm Proteins; Neovascularization, Pathologic; Organoplatinum Compounds; Oxaliplatin; Purines; Quinazolines; RNA, Small Interfering; Treatment Outcome; Vascular Endothelial Growth Factor A | 2009 |
Safety of capecitabine use in patients with liver dysfunction.
Topics: Antimetabolites, Antineoplastic; Capecitabine; Carcinoma, Hepatocellular; Deoxycytidine; Drug-Related Side Effects and Adverse Reactions; Female; Fluorouracil; Humans; Liver Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Pancreatic Neoplasms | 2007 |
[Recent developments in systemic chemotherapy for hepatocellular carcinoma].
Topics: Antibodies, Monoclonal; Antimetabolites, Antineoplastic; Antineoplastic Agents, Hormonal; Capecitabine; Carcinoma, Hepatocellular; Combined Modality Therapy; Deoxycytidine; Fluorouracil; Humans; Immunologic Factors; Liver Neoplasms; Tegafur | 2008 |
Nonsurgical treatment of hepatocellular carcinoma.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Capecitabine; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Cryosurgery; Deoxycytidine; Drug Combinations; Ethanol; Fluorouracil; Humans; Hyperthermia, Induced; Infusions, Intra-Arterial; Injections, Intralesional; Interferons; Liver Cirrhosis; Liver Neoplasms; Octreotide; Radiopharmaceuticals; Radiotherapy Dosage; Tamoxifen; Tegafur; Uracil | 2001 |
15 trial(s) available for capecitabine and Carcinoma, Hepatocellular
| Article | Year |
|---|---|
Sintilimab combined with apatinib plus capecitabine in the treatment of unresectable hepatocellular carcinoma: A prospective, open-label, single-arm, phase II clinical study.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Capecitabine; Carcinoma, Hepatocellular; Humans; Liver Neoplasms; Prospective Studies; Pyridines; Treatment Outcome | 2022 |
A Phase II Clinical Trial on the Combination Therapy of PHY906 Plus Capecitabine in Hepatocellular Carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, Hepatocellular; Drugs, Chinese Herbal; Fluorouracil; Humans; Liver Neoplasms; Treatment Outcome | 2021 |
Phase II Trial of Sorafenib in Combination with Capecitabine in Patients with Hepatocellular Carcinoma: INST 08-20.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Capecitabine; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Sorafenib | 2017 |
Communicative reprogramming non-curative hepatocellular carcinoma with low-dose metronomic chemotherapy, COX-2 inhibitor and PPAR-gamma agonist: a phase II trial.
Topics: Administration, Metronomic; Aged; alpha-Fetoproteins; Antineoplastic Combined Chemotherapy Protocols; C-Reactive Protein; Capecitabine; Carcinoma, Hepatocellular; Cyclooxygenase 2 Inhibitors; Disease-Free Survival; Female; Humans; Lactones; Liver Neoplasms; Male; Middle Aged; Pioglitazone; PPAR gamma; Sulfones; Thiazolidinediones; Treatment Outcome | 2017 |
Sorafenib versus capecitabine in the management of advanced hepatocellular carcinoma.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Capecitabine; Carcinoma, Hepatocellular; Deoxycytidine; Disease-Free Survival; Fluorouracil; Humans; Liver Neoplasms; Middle Aged; Niacinamide; Phenylurea Compounds; Sorafenib | 2013 |
Metronomic capecitabine in advanced hepatocellular carcinoma patients: a phase II study.
Topics: Administration, Metronomic; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Capecitabine; Carcinoma, Hepatocellular; Deoxycytidine; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Fluorouracil; Humans; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Sorafenib; Treatment Outcome | 2013 |
A phase I/II trial of capecitabine combined with peginterferon α-2a in Patients with sorafenib-refractory advanced hepatocellular carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, Hepatocellular; Deoxycytidine; Female; Fluorouracil; Humans; Interferon-alpha; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Polyethylene Glycols; Recombinant Proteins; Sorafenib | 2014 |
Clinical efficacy of metronomic chemotherapy after cool-tip radiofrequency ablation in the treatment of hepatocellular carcinoma.
Topics: Administration, Metronomic; Adult; Aged; Antineoplastic Agents; Capecitabine; Carcinoma, Hepatocellular; Catheter Ablation; Combined Modality Therapy; Disease-Free Survival; Endothelial Cells; Female; Humans; Liver Neoplasms; Male; Middle Aged; Thalidomide; Treatment Outcome; Vascular Endothelial Growth Factor A | 2016 |
Phase I/II study of PHY906/capecitabine in advanced hepatocellular carcinoma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, Hepatocellular; Deoxycytidine; Dose-Response Relationship, Drug; Drugs, Chinese Herbal; Female; Fluorouracil; Humans; Liver Neoplasms; Male; Middle Aged; Quality of Life; Survival Rate | 2009 |
Efficacy and tolerability of bevacizumab plus capecitabine as first-line therapy in patients with advanced hepatocellular carcinoma.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Capecitabine; Carcinoma, Hepatocellular; Deoxycytidine; Disease Progression; Female; Fluorouracil; Humans; Liver Neoplasms; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Survival Analysis; Treatment Outcome; Young Adult | 2010 |
Adjuvant therapy with capecitabine postpones recurrence of hepatocellular carcinoma after curative resection: a randomized controlled trial.
Topics: Adolescent; Adult; Aged; Antimetabolites, Antineoplastic; Capecitabine; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Combined Modality Therapy; Deoxycytidine; Female; Fluorouracil; Follow-Up Studies; Hepatectomy; Humans; Liver Neoplasms; Male; Middle Aged; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Neoplasm Staging; Postoperative Care; Prospective Studies; Survival Rate; Treatment Outcome; Young Adult | 2010 |
Phase 2 trial of bevacizumab, capecitabine, and oxaliplatin in treatment of advanced hepatocellular carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Capecitabine; Carcinoma, Hepatocellular; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Humans; Liver Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin | 2011 |
Pegylated liposomal doxorubicin-based combination chemotherapy as salvage treatment in patients with advanced hepatocellular carcinoma.
Topics: Adult; Aged; alpha-Fetoproteins; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Capecitabine; Carcinoma, Hepatocellular; Deoxycytidine; Doxorubicin; Fatigue; Female; Fluorouracil; Gemcitabine; Hepatitis B, Chronic; Humans; Liposomes; Liver Neoplasms; Lung Neoplasms; Male; Middle Aged; Mucositis; Neoplasm Proteins; Paresthesia; Polyethylene Glycols; Salvage Therapy; Survival Analysis; Treatment Outcome | 2005 |
Systemic chemotherapy with doxorubicin, cisplatin and capecitabine for metastatic hepatocellular carcinoma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, Hepatocellular; Cisplatin; Deoxycytidine; Doxorubicin; Fluorouracil; Humans; Liver Neoplasms; Middle Aged; Treatment Outcome | 2006 |
Multicentre phase II trial of capecitabine plus oxaliplatin (XELOX) in patients with advanced hepatocellular carcinoma: FFCD 03-03 trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, Hepatocellular; Deoxycytidine; Drug Combinations; Female; Fluorouracil; Humans; Liver Neoplasms; Male; Middle Aged; Organoplatinum Compounds; Oxaloacetates; Prognosis; Survival Rate; Treatment Outcome | 2007 |
38 other study(ies) available for capecitabine and Carcinoma, Hepatocellular
| Article | Year |
|---|---|
Metronomic capecitabine with rapamycin exerts an immunosuppressive effect by inducing ferroptosis of CD4
Topics: Animals; Capecitabine; Carcinoma, Hepatocellular; CD4-Positive T-Lymphocytes; Ferroptosis; Humans; Liver Neoplasms; Liver Transplantation; Neoplasm Recurrence, Local; Rats; Sirolimus; T-Lymphocytes | 2023 |
Yttrium-90 transarterial radioembolization and capecitabine in hepatocellular carcinoma with portal vein involvement.
Topics: Capecitabine; Carcinoma, Hepatocellular; Humans; Liver Neoplasms; Portal Vein; Retrospective Studies | 2023 |
Differential expression of Tim-3, PD-1, and CCR5 on peripheral T and B lymphocytes in hepatitis C virus-related hepatocellular carcinoma and their impact on treatment outcomes.
Topics: Antineoplastic Combined Chemotherapy Protocols; B-Lymphocytes; Biomarkers, Tumor; Capecitabine; Carcinoma, Hepatocellular; Case-Control Studies; Female; Follow-Up Studies; Hepacivirus; Hepatitis A Virus Cellular Receptor 2; Hepatitis C; Humans; Liver Neoplasms; Male; Middle Aged; Prognosis; Programmed Cell Death 1 Receptor; Receptors, CCR5; Sorafenib; Survival Rate; T-Lymphocytes | 2020 |
Systemic therapies in elderly patients with advanced hepatocellular carcinoma: Do not forget metronomic capecitabine.
Topics: Aged; Antimetabolites, Antineoplastic; Capecitabine; Carcinoma, Hepatocellular; Humans; Liver Neoplasms; Treatment Outcome | 2021 |
Systemic therapies in elderly patients with advanced hepatocellular carcinoma: do not forget metronomic capecitabine.
Topics: Aged; Antimetabolites, Antineoplastic; Capecitabine; Carcinoma, Hepatocellular; Humans; Liver Neoplasms; Treatment Outcome | 2021 |
The power of kindness: curative treatment with metronomic combination in advanced hepatocellular carcinoma.
Topics: Administration, Metronomic; Adult; alpha-Fetoproteins; Antimetabolites, Antineoplastic; Capecitabine; Carcinoma, Hepatocellular; Hepatitis B; Hepatitis D; Humans; Liver Neoplasms; Male; Patient Acuity | 2022 |
Metastatic Hepatoid Carcinoma of the Pancreas: First Description of Treatment With Capecitabine and Temozolomide.
Topics: Adult; Antimetabolites, Antineoplastic; Antineoplastic Agents, Alkylating; Biopsy; Capecitabine; Carcinoma, Hepatocellular; Dacarbazine; Glucagon; Glucagonoma; Humans; Jaundice; Liver; Male; Neoplasm Metastasis; Pancreatic Neoplasms; Prognosis; Temozolomide; Treatment Outcome | 2017 |
The role of metronomic capecitabine for treatment of recurrent hepatocellular carcinoma after liver transplantation.
Topics: Administration, Metronomic; Adult; Aged; Antimetabolites, Antineoplastic; Capecitabine; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Liver Transplantation; Male; Middle Aged; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Neoplasm Staging; Sorafenib; Survival Analysis; Treatment Outcome | 2017 |
Metronomic capecitabine as second-line treatment for hepatocellular carcinoma after sorafenib discontinuation.
Topics: Administration, Metronomic; Aged; Antimetabolites, Antineoplastic; Capecitabine; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Retrospective Studies; Sorafenib; Survival Rate | 2018 |
Sustained complete response of advanced hepatocellular carcinoma with metronomic capecitabine: a report of three cases.
Topics: Administration, Metronomic; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Capecitabine; Carcinoma, Hepatocellular; Humans; Liver; Liver Neoplasms; Male; Protein Kinase Inhibitors; Remission Induction; Sorafenib; Treatment Outcome | 2018 |
Metronomic capecitabine vs. best supportive care in Child-Pugh B hepatocellular carcinoma: a proof of concept.
Topics: Administration, Metronomic; Adult; Aged; Aged, 80 and over; Capecitabine; Carcinoma, Hepatocellular; Female; Humans; Liver Cirrhosis; Liver Diseases; Liver Neoplasms; Male; Middle Aged; Proof of Concept Study; Propensity Score; Prospective Studies; Retrospective Studies; Survival Rate; Treatment Outcome | 2018 |
Capecitabine in advanced hepatocellular carcinoma: A multicenter experience.
Topics: Administration, Metronomic; Antimetabolites, Antineoplastic; Capecitabine; Carcinoma, Hepatocellular; Dose-Response Relationship, Drug; Drug Monitoring; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Italy; Liver Neoplasms; Male; Middle Aged; Neoplasm Staging; Retrospective Studies; Treatment Outcome | 2019 |
Efficacy of capecitabine and oxaliplatin regimen for extrahepatic metastasis of hepatocellular carcinoma following local treatments.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, Hepatocellular; Deoxycytidine; Disease Progression; Female; Fluorouracil; Humans; Kaplan-Meier Estimate; Liver Neoplasms; Male; Middle Aged; Multivariate Analysis; Organoplatinum Compounds; Oxaliplatin; Prospective Studies; Risk Factors; Time Factors; Treatment Outcome; Young Adult | 2013 |
Systemic cytotoxic chemotherapy of patients with advanced hepatocellular carcinoma in the era of sorafenib nonavailability.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, Hepatocellular; Cisplatin; Deoxycytidine; Disease Progression; Disease-Free Survival; Doxorubicin; Female; Fluorouracil; Humans; Kaplan-Meier Estimate; Liver Neoplasms; Male; Middle Aged; Molecular Targeted Therapy; Niacinamide; Phenylurea Compounds; Proportional Hazards Models; Protein Kinase Inhibitors; Retrospective Studies; Risk Factors; Signal Transduction; Sorafenib; Time Factors; Treatment Outcome | 2014 |
Long-term disease-free survival achieved by anti-angiogenic therapy plus surgery in a hepatocellular carcinoma patient with extensive liver involvement and lung metastases.
Topics: Adult; alpha-Fetoproteins; Angiogenesis Inhibitors; Antimetabolites, Antineoplastic; Bevacizumab; Capecitabine; Carcinoma, Hepatocellular; Disease-Free Survival; Female; Hepatectomy; Humans; Liver Neoplasms; Lung Neoplasms; Splenic Neoplasms; Young Adult | 2014 |
Metronomic capecitabine as second-line treatment in hepatocellular carcinoma after sorafenib failure.
Topics: Administration, Metronomic; Aged; Antineoplastic Agents; Capecitabine; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Retrospective Studies; Sorafenib; Survival Analysis; Treatment Failure | 2015 |
Capecitabine in advanced hepatocellular carcinoma.
Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Capecitabine; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Sorafenib; Survival Analysis | 2016 |
Capecitabine and the Risk of Fingerprint Loss.
Topics: Capecitabine; Carcinoma, Hepatocellular; Colorectal Neoplasms; Dermatoglyphics; Female; Fluorouracil; Hand-Foot Syndrome; Humans; Liver Neoplasms; Male; Skin Diseases, Genetic | 2017 |
Metronomic capecitabine versus best supportive care as second-line treatment in hepatocellular carcinoma: a retrospective study.
Topics: Administration, Metronomic; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Capecitabine; Carcinoma, Hepatocellular; Combined Modality Therapy; Female; Humans; Liver Neoplasms; Male; Middle Aged; Neoplasm Staging; Proportional Hazards Models; Retreatment; Retrospective Studies; Treatment Outcome | 2017 |
Combination chemotherapy with capecitabine and cisplatin for patients with metastatic hepatocellular carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, Hepatocellular; Cisplatin; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Follow-Up Studies; Humans; Liver Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Survival Rate | 2009 |
Accelerated treatment using intensity-modulated radiation therapy plus concurrent capecitabine for unresectable hepatocellular carcinoma.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Capecitabine; Carcinoma, Hepatocellular; Combined Modality Therapy; Deoxycytidine; Feasibility Studies; Female; Fluorouracil; Follow-Up Studies; Humans; Liver Neoplasms; Male; Middle Aged; Radiotherapy; Radiotherapy Dosage; Radiotherapy Planning, Computer-Assisted; Treatment Outcome | 2009 |
Clinical outcomes of sorafenib treatment in patients with metastatic hepatocellular carcinoma who had been previously treated with fluoropyrimidine plus platinum-based chemotherapy.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Capecitabine; Carcinoma, Hepatocellular; Cisplatin; Deoxycytidine; Drug-Related Side Effects and Adverse Reactions; Female; Fluorouracil; Humans; Liver Neoplasms; Male; Middle Aged; Multivariate Analysis; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Proportional Hazards Models; Pyridines; Republic of Korea; Retrospective Studies; Risk Factors; Sorafenib; Survival Analysis; Treatment Failure | 2011 |
Activity of thalidomide and capecitabine in patients with advanced hepatocellular carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, Hepatocellular; Deoxycytidine; Female; Fluorouracil; Follow-Up Studies; Humans; Liver Neoplasms; Male; Middle Aged; Neoplasm Staging; Prognosis; Retrospective Studies; Survival Rate; Thalidomide | 2012 |
Arsenic trioxide plus cisplatin/interferon α-2b/doxorubicin/capecitabine combination chemotherapy for unresectable hepatocellular carcinoma.
Topics: AC133 Antigen; Antigens, CD; Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Capecitabine; Carcinoma, Hepatocellular; Cell Line; Cisplatin; Deoxycytidine; Doxorubicin; Drug Resistance, Neoplasm; Fluorescent Dyes; Fluorouracil; Glycoproteins; Hep G2 Cells; Humans; Immunohistochemistry; Interferon-alpha; Liver Neoplasms; Oxides; Peptides; Rhodamine 123; Thy-1 Antigens | 2011 |
Serum insulin-like growth factor-1 levels predict outcomes of patients with advanced hepatocellular carcinoma receiving antiangiogenic therapy.
Topics: Administration, Metronomic; Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Capecitabine; Carcinoma, Hepatocellular; Clinical Trials as Topic; Deoxycytidine; Fluorouracil; Humans; Insulin-Like Growth Factor I; Liver Neoplasms; Male; Middle Aged; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Prognosis; Serum; Sorafenib; Tegafur; Treatment Outcome | 2012 |
Gold nanoparticles conjugated with cisplatin/doxorubicin/capecitabine lower the chemoresistance of hepatocellular carcinoma-derived cancer cells.
Topics: Antineoplastic Agents; Apoptosis; Capecitabine; Carcinoma, Hepatocellular; Cell Death; Cell Proliferation; Cisplatin; Deoxycytidine; Doxorubicin; Drug Delivery Systems; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Fluorouracil; Gold; Humans; Liver Neoplasms; Metal Nanoparticles; Microscopy, Electron, Transmission; Tumor Cells, Cultured | 2012 |
Radiotherapy for nasopharyngeal carcinoma and combined capecitabine and nimotuzumab treatment for lung metastases in a liver transplantation recipient: a case experience of sustained complete response.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma; Carcinoma, Hepatocellular; Combined Modality Therapy; Deoxycytidine; Fluorouracil; Humans; Liver Neoplasms; Liver Transplantation; Lung Neoplasms; Male; Middle Aged; Nasopharyngeal Carcinoma; Nasopharyngeal Neoplasms; Radiotherapy Dosage; Radiotherapy, Intensity-Modulated | 2012 |
Hypofractionated radiotheapy using helical tomotherapy for advanced hepatocellular carcinoma with portal vein tumor thrombosis.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Capecitabine; Carcinoma, Hepatocellular; Chemoradiotherapy; Deoxycytidine; Dose Fractionation, Radiation; Female; Fluorouracil; Follow-Up Studies; Humans; Liver Neoplasms; Male; Middle Aged; Neoplasm Staging; Prognosis; Radiotherapy, Conformal; Radiotherapy, Intensity-Modulated; Tomography, X-Ray Computed; Venous Thrombosis | 2013 |
Capecitabine inhibits postoperative recurrence and metastasis after liver cancer resection in nude mice with relation to the expression of platelet-derived endothelial cell growth factor.
Topics: Animals; Antimetabolites, Antineoplastic; Capecitabine; Carcinoma, Hepatocellular; Deoxycytidine; Fluorouracil; Humans; Liver Neoplasms, Experimental; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasm Metastasis; Neoplasm Recurrence, Local; Postoperative Care; Thymidine Phosphorylase; Transplantation, Heterologous | 2003 |
Interferon-alpha 2a up-regulated thymidine phosphorylase and enhanced antitumor effect of capecitabine on hepatocellular carcinoma in nude mice.
Topics: Animals; Antimetabolites, Antineoplastic; Capecitabine; Carcinoma, Hepatocellular; Deoxycytidine; Enzyme-Linked Immunosorbent Assay; Fluorouracil; Gene Expression Regulation, Enzymologic; Gene Expression Regulation, Neoplastic; Humans; Interferon-alpha; Liver Neoplasms; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Thymidine Phosphorylase; Transplantation, Heterologous; Up-Regulation | 2004 |
Oral capecitabine for the treatment of hepatocellular carcinoma, cholangiocarcinoma, and gallbladder carcinoma.
Topics: Administration, Oral; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Capecitabine; Carcinoma, Hepatocellular; Cholangiocarcinoma; Cohort Studies; Deoxycytidine; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Fluorouracil; Follow-Up Studies; Gallbladder Neoplasms; Humans; Liver Neoplasms; Male; Multivariate Analysis; Probability; Proportional Hazards Models; Retrospective Studies; Survival Analysis; Treatment Outcome | 2004 |
Toxic death-case after capecitabine + oxaliplatin (XELOX) administration: probable implication of dihydropyrimidine deshydrogenase deficiency.
Topics: Antineoplastic Combined Chemotherapy Protocols; Base Sequence; Capecitabine; Carcinoma, Hepatocellular; Deoxycytidine; Dihydropyrimidine Dehydrogenase Deficiency; Dihydrouracil Dehydrogenase (NADP); DNA Primers; Fluorouracil; Humans; Liver Neoplasms; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Polymorphism, Single Nucleotide; Tomography, X-Ray Computed | 2006 |
Hepatocellular carcinoma--Pathological complete response to oral capecitabine, megestrol and thalidomide.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, Hepatocellular; Deoxycytidine; Disease Progression; Fluorouracil; Humans; Male; Megestrol; Thalidomide; Treatment Outcome | 2006 |
Is capecitabine safe in patients with gastrointestinal cancer and dihydropyrimidine dehydrogenase deficiency?
Topics: Antimetabolites, Antineoplastic; Capecitabine; Carcinoma, Hepatocellular; Contraindications; Deoxycytidine; Dihydropyrimidine Dehydrogenase Deficiency; Fatal Outcome; Female; Fluorouracil; Humans; Liver Neoplasms; Middle Aged; Pancreatic Neoplasms | 2006 |
Oxaliplatin and capecitabine (Xelox) in association with highly active antiretroviral therapy in advanced hepatocarcinoma HIV/HCV-infected patients.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Antiretroviral Therapy, Highly Active; Capecitabine; Carcinoma, Hepatocellular; Deoxycytidine; Drug Therapy, Combination; Female; Fluorouracil; Hepatitis C; HIV Infections; Humans; Liver Neoplasms; Male; Middle Aged; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Prodrugs | 2006 |
Capecitabine for treatment of advanced hepatocellular carcinoma.
Topics: Aged; Antimetabolites, Antineoplastic; Bilirubin; Capecitabine; Carcinoma, Hepatocellular; Deoxycytidine; Disease Progression; Female; Fluorouracil; Humans; Liver Cirrhosis; Liver Neoplasms; Male; Middle Aged; Treatment Outcome | 2007 |
Efficacy of combination chemotherapy with capecitabine plus cisplatin in patients with unresectable hepatocellular carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, Hepatocellular; Cisplatin; Deoxycytidine; Female; Fluorouracil; Humans; Liver Neoplasms; Male; Middle Aged; Survival Analysis | 2009 |
[The expression of platelet-derived endothelial cell growth factor in liver cancer].
Topics: Animals; Antimetabolites, Antineoplastic; Capecitabine; Carcinoma, Hepatocellular; Deoxycytidine; Endothelial Growth Factors; Fluorouracil; Humans; Liver Neoplasms; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasm Metastasis; Platelet-Derived Growth Factor | 2000 |